Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is now a common cause of cancer death, with no obvious change in patient survival over the past few years. Although the traditional therapeutic modalities for HCC patients mainly involved in surgery, chemotherapy, and radiotherapy, which have achieved admirable achieve...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | Asian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087623000557 |
| _version_ | 1827821606930481152 |
|---|---|
| author | Shijing Yu Ruirui Zhao Bingchen Zhang Chunmei Lai Linyan Li Jiangwen Shen Xiarong Tan Jingwei Shao |
| author_facet | Shijing Yu Ruirui Zhao Bingchen Zhang Chunmei Lai Linyan Li Jiangwen Shen Xiarong Tan Jingwei Shao |
| author_sort | Shijing Yu |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is now a common cause of cancer death, with no obvious change in patient survival over the past few years. Although the traditional therapeutic modalities for HCC patients mainly involved in surgery, chemotherapy, and radiotherapy, which have achieved admirable achievements, challenges are still existed, such as drug resistance and toxicity. The emerging gene therapy of clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9-based (CRISPR/Cas9), as an alternative to traditional treatment methods, has attracted considerable attention for eradicating resistant malignant tumors and regulating multiple crucial events of target gene-editing. Recently, advances in CRISPR/Cas9-based anti-drugs are presented at the intersection of science, such as chemistry, materials science, tumor biology, and genetics. In this review, the principle as well as statues of CRISPR/Cas9 technique were introduced first to show its feasibility. Additionally, the emphasis was placed on the applications of CRISPR/Cas9 technology in therapeutic HCC. Further, a broad overview of non-viral delivery systems for the CRISPR/Cas9-based anti-drugs in HCC treatment was summarized to delineate their design, action mechanisms, and anticancer applications. Finally, the limitations and prospects of current studies were also discussed, and we hope to provide comprehensively theoretical basis for the designing of anti-drugs. |
| first_indexed | 2024-03-12T01:47:45Z |
| format | Article |
| id | doaj.art-c58eb4c7222b4175b8c3c1e9fd898b50 |
| institution | Directory Open Access Journal |
| issn | 1818-0876 |
| language | English |
| last_indexed | 2024-03-12T01:47:45Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-c58eb4c7222b4175b8c3c1e9fd898b502023-09-09T04:54:53ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762023-07-01184100828Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinomaShijing Yu0Ruirui Zhao1Bingchen Zhang2Chunmei Lai3Linyan Li4Jiangwen Shen5Xiarong Tan6Jingwei Shao7Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, ChinaFujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, ChinaFujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, ChinaFujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, ChinaFujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, ChinaFujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, ChinaFujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, ChinaFujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, China; College of Materials and Chemical Engineering, Minjiang University, Fuzhou 350108, China; Corresponding author.Hepatocellular carcinoma (HCC) is now a common cause of cancer death, with no obvious change in patient survival over the past few years. Although the traditional therapeutic modalities for HCC patients mainly involved in surgery, chemotherapy, and radiotherapy, which have achieved admirable achievements, challenges are still existed, such as drug resistance and toxicity. The emerging gene therapy of clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9-based (CRISPR/Cas9), as an alternative to traditional treatment methods, has attracted considerable attention for eradicating resistant malignant tumors and regulating multiple crucial events of target gene-editing. Recently, advances in CRISPR/Cas9-based anti-drugs are presented at the intersection of science, such as chemistry, materials science, tumor biology, and genetics. In this review, the principle as well as statues of CRISPR/Cas9 technique were introduced first to show its feasibility. Additionally, the emphasis was placed on the applications of CRISPR/Cas9 technology in therapeutic HCC. Further, a broad overview of non-viral delivery systems for the CRISPR/Cas9-based anti-drugs in HCC treatment was summarized to delineate their design, action mechanisms, and anticancer applications. Finally, the limitations and prospects of current studies were also discussed, and we hope to provide comprehensively theoretical basis for the designing of anti-drugs.http://www.sciencedirect.com/science/article/pii/S1818087623000557Hepatocellular carcinomaCRISPR/Cas9Screen geneDelivery strategy |
| spellingShingle | Shijing Yu Ruirui Zhao Bingchen Zhang Chunmei Lai Linyan Li Jiangwen Shen Xiarong Tan Jingwei Shao Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma Asian Journal of Pharmaceutical Sciences Hepatocellular carcinoma CRISPR/Cas9 Screen gene Delivery strategy |
| title | Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma |
| title_full | Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma |
| title_fullStr | Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma |
| title_full_unstemmed | Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma |
| title_short | Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma |
| title_sort | research progress and application of the crispr cas9 gene editing technology based on hepatocellular carcinoma |
| topic | Hepatocellular carcinoma CRISPR/Cas9 Screen gene Delivery strategy |
| url | http://www.sciencedirect.com/science/article/pii/S1818087623000557 |
| work_keys_str_mv | AT shijingyu researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma AT ruiruizhao researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma AT bingchenzhang researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma AT chunmeilai researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma AT linyanli researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma AT jiangwenshen researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma AT xiarongtan researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma AT jingweishao researchprogressandapplicationofthecrisprcas9geneeditingtechnologybasedonhepatocellularcarcinoma |